Dupilumab, a Potential Novel Treatment for Hailey–Hailey Disease DOI Creative Commons
Liliana Gabriela Popa, Călin Giurcăneanu,

Florentina Zaharia

и другие.

Clinics and Practice, Год журнала: 2025, Номер 15(3), С. 48 - 48

Опубликована: Фев. 26, 2025

Background/Objectives: Hailey–Hailey disease (HHD) is an uncommon genodermatosis with autosomal dominant inheritance caused by loss-of-function mutations in the ATP2C1 gene, which lead to disruption keratinocyte adhesion and intraepidermal acantholysis. The chronic nature of disease, its frequent recurrences lack specific treatment pose real challenges long-term management these patients. Recent studies have evaluated effect dupilumab, a human monoclonal antibody that blocks interleukin-4 -13 receptor refractory HHD, very promising results. aim this study was review published data on use dupilumab for present our own experience field, discuss mechanisms underlying dupilumab’s beneficial effects HHD future perspectives. Methods: A search medical literature conducted. terms “Hailey–Hailey disease”, “benign familial pemphigus”, “dupilumab” were searched across multiple databases (Medline, Chrocane Library, EMBASE) from inception until 30 September 2024. Results: To date, six manuscripts describing 11 cases treated been published. All patients experienced significant clinical improvement. authors reported sustained quiescence seven (64%), monitored 5 24 months. None adverse related dupilumab. existing evidence, we add new case recalcitrant successfully Conclusions: Mounting evidence indicates as safe efficient therapeutic alternative severe, HHD. However, efficacy optimal regimen are yet be determined.

Язык: Английский

Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights DOI Creative Commons
Heidi M. Abdel-Mageed

Inflammopharmacology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 7, 2025

Язык: Английский

Процитировано

2
RECENT DEVELOPMENTS AND ADVANCES IN ATOPIC DERMATITIS: FOCUS ON EPIDEMIOLOGY, PATHOPHYSIOLOGY AND TREATMENT IN THE CONTEXT DOI Open Access

A. Toledo,

Maria Isabel de Brito Theodoro,

Isabela Marangoni Cremonezi

и другие.

International Journal of Health Science, Год журнала: 2025, Номер 5(4), С. 1 - 6

Опубликована: Янв. 15, 2025

Objective: To review and synthesize the most recent advances in understanding of atopic dermatitis children adolescents, with a specific focus on epidemiological aspects, underlying pathophysiological mechanisms effective therapeutic approaches, order to provide an informed basis for future clinical strategies.Methodology: Bibliographic developed using PubMed database according search strategy: ("Pediatric dermatitis") OR (((children) (pediatric)) AND (atopic) (dermatitis)) (treatment)), resulting 2226 articles.After applying inclusion exclusion criteria, 16 articles published between 2019 2024 were included.Discussion: Atopic (AD) is chronic inflammatory skin condition characterized by intense pruritus, erythema, papules nodules, whose pathophysiology multifactorial, involving genetic, immunological environmental factors.In years, have focused development innovative biological treatments, such as monoclonal antibodies targeting type 2 inflammation, which plays central role perpetuating inflammation AD.These therapies shown significant efficacy reducing exacerbations, controlling lesions infectious complications, well improving quality life pediatric patients.Final considerations: There are still gaps management AD due limited availability licensed lack biomarkers.These limitations highlight need longitudinal studies further research into more precise approaches.Personalization treatment, coupled active involvement family daily care, fundamental stages enhancing patients' life.

Язык: Английский

Процитировано

0
Dupilumab, a Potential Novel Treatment for Hailey–Hailey Disease DOI Creative Commons
Liliana Gabriela Popa, Călin Giurcăneanu,

Florentina Zaharia

и другие.

Clinics and Practice, Год журнала: 2025, Номер 15(3), С. 48 - 48

Опубликована: Фев. 26, 2025

Background/Objectives: Hailey–Hailey disease (HHD) is an uncommon genodermatosis with autosomal dominant inheritance caused by loss-of-function mutations in the ATP2C1 gene, which lead to disruption keratinocyte adhesion and intraepidermal acantholysis. The chronic nature of disease, its frequent recurrences lack specific treatment pose real challenges long-term management these patients. Recent studies have evaluated effect dupilumab, a human monoclonal antibody that blocks interleukin-4 -13 receptor refractory HHD, very promising results. aim this study was review published data on use dupilumab for present our own experience field, discuss mechanisms underlying dupilumab’s beneficial effects HHD future perspectives. Methods: A search medical literature conducted. terms “Hailey–Hailey disease”, “benign familial pemphigus”, “dupilumab” were searched across multiple databases (Medline, Chrocane Library, EMBASE) from inception until 30 September 2024. Results: To date, six manuscripts describing 11 cases treated been published. All patients experienced significant clinical improvement. authors reported sustained quiescence seven (64%), monitored 5 24 months. None adverse related dupilumab. existing evidence, we add new case recalcitrant successfully Conclusions: Mounting evidence indicates as safe efficient therapeutic alternative severe, HHD. However, efficacy optimal regimen are yet be determined.

Язык: Английский

Процитировано

0